Physiologic indirect response models characterize diverse types of pharmacodynamic effects
- PMID: 7955802
- DOI: 10.1038/clpt.1994.155
Physiologic indirect response models characterize diverse types of pharmacodynamic effects
Abstract
A family of four basic physiologic indirect response models has been proposed to account for the pharmacodynamics of drugs that act by way of inhibition or stimulation of the production or loss of endogenous substances or mediators. Such models were applied previously to account for the anticoagulant effects of warfarin, adrenal suppression by corticosteroids, cell trafficking effects of corticosteroids, antipyretic effects of ibuprofen, and aldose reductase inhibition. Additional responses that can be readily characterized with such models include muscular contraction from pyridostigmine, diuresis from furosemide, bronchodilation from terbutaline, prolactin secretion after cimetidine, and potassium suppression by terbutaline. This report shows that indirect response models, rather than "link" or "hypothetical effect compartment" models, may be more appropriate for diverse drugs when time lags exist between plasma or biophase drug concentrations and the time course of pharmacodynamic responses.
Comment in
-
Further notes on physiologic indirect response models.Clin Pharmacol Ther. 1995 Aug;58(2):238-40. doi: 10.1016/0009-9236(95)90203-1. Clin Pharmacol Ther. 1995. PMID: 7648775 No abstract available.
Similar articles
-
Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.Pharmacol Rev. 2020 Apr;72(2):414-438. doi: 10.1124/pr.119.018101. Pharmacol Rev. 2020. PMID: 32123034 Free PMC article. Review.
-
Characteristics of indirect pharmacodynamic models and applications to clinical drug responses.Br J Clin Pharmacol. 1998 Mar;45(3):229-39. doi: 10.1046/j.1365-2125.1998.00676.x. Br J Clin Pharmacol. 1998. PMID: 9517366 Free PMC article. Review.
-
Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses.J Pharmacokinet Biopharm. 1997 Feb;25(1):107-23. doi: 10.1023/a:1025723927981. J Pharmacokinet Biopharm. 1997. PMID: 9353696
-
Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.Int J Clin Pharmacol Ther. 1997 Oct;35(10):401-13. Int J Clin Pharmacol Ther. 1997. PMID: 9352388 Review.
-
Role of dosage regimen in controlling indirect pharmacodynamic responses.Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):45-57. doi: 10.1016/s0169-409x(00)00132-0. Adv Drug Deliv Rev. 2001. PMID: 11259832
Cited by
-
Volterra series in pharmacokinetics and pharmacodynamics.J Pharmacokinet Pharmacodyn. 2003 Oct;30(5):337-62. doi: 10.1023/b:jopa.0000008158.30235.59. J Pharmacokinet Pharmacodyn. 2003. PMID: 14977164
-
Modeling the endocrine control of vitellogenin production in female rainbow trout.Math Biosci Eng. 2014 Jun;11(3):621-39. doi: 10.3934/mbe.2014.11.621. Math Biosci Eng. 2014. PMID: 24506554 Free PMC article.
-
Expanding clinical applications of population pharmacodynamic modelling.Br J Clin Pharmacol. 1998 Oct;46(4):321-33. doi: 10.1046/j.1365-2125.1998.00792.x. Br J Clin Pharmacol. 1998. PMID: 9803979 Free PMC article. Review.
-
Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.Pharm Res. 1999 Feb;16(2):176-85. doi: 10.1023/a:1011907920641. Pharm Res. 1999. PMID: 10100300
-
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.AAPS J. 2011 Dec;13(4):598-605. doi: 10.1208/s12248-011-9299-0. Epub 2011 Sep 13. AAPS J. 2011. PMID: 21913053 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources